3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
9
Stomach Neoplasms
8
Carcinoma, Hepatocellular
8
Neoplasm Metastasis
7
Triple Negative Breast Neoplasms
6
Rectal Neoplasms
6
Nasopharyngeal Carcinoma
6
Melanoma
6
Lymphoma, Extranodal NK-T-Cell
6
Locally Advanced Rectal Cancer
6
Colorectal Neoplasms
6
Carcinoma, Renal Cell
6
Squamous Cell Carcinoma of Head and Neck
5
Sarcoma
5
Pancreatic Neoplasms
4
Uterine Cervical Neoplasms
3
Small Cell Lung Carcinoma
3
Cholangiocarcinoma
3
Thyroid Neoplasms
2
Nasopharyngeal Neoplasms
2
Lymphoma, Large B-Cell, Diffuse
2
Kidney Neoplasms
2
Hemangiosarcoma
2
Gastrointestinal Stromal Tumors
2
Esophageal Squamous Cell Carcinoma
2
Esophageal Neoplasms
2
Adenocarcinoma Of Esophagus
2
Uveal Melanoma
1
Urinary Bladder Neoplasms
1
Turcot syndrome
1
Interventions
Oxaliplatin
26
Gemcitabine
22
Fluorouracil
17
Capecitabine
16
Leucovorin
15
pembrolizumab
14
Docetaxel
14
Cisplatin
13
Bevacizumab
12
Radiotherapy
8
Paclitaxel
8
Irinotecan
8
Trastuzumab
7
Pemetrexed
6
Carboplatin
6
130-nm albumin-bound paclitaxel
6
durvalumab
5
cemiplimab
5
Erlotinib Hydrochloride
5
Sunitinib
4
Ramucirumab
4
Metformin
4
Gefitinib
4
trastuzumab deruxtecan
3
tislelizumab
3
cabozantinib
3
atezolizumab
3
Taxes
3
Sorafenib
3
Panitumumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Adenocarcinoma
×
spartalizumab
×
Clear all
NCT06121700
2023-11-08
Miracle-G
Fudan University
Phase 2
Recruiting
55 enrolled